Literature DB >> 7105424

An improved method for the routine biochemical evaluation of patients with recurrent calcium oxalate stone disease.

H G Tiselius.   

Abstract

By means of a computerized calculation program, a simplified estimate of the ion-activity product of calcium oxalate was derived (AP(CaOx)-index), based on the 24-h urinary excretion of calcium (Ca), oxalate (Ox), magnesium (Mg), citrate (Cit) and the urine volume (V): (formula: see text) With urinary electrolyte values within the normal range, there was a good correlation between the AP(CaOx)-index and the more laboriously obtained ion-activity product (r = 0.997). To express the biochemical risk of CaOx stone formation a CaOx-risk index was designed, which also includes the inhibition of calcium oxalate crystal growth (I) and with all variables related to urinary creatinine (Cr): (formula: see text) The mean CaOx-risk index (+/-SEM) in urine from 100 normal men and 156 male stone formers were 648 +/- 27 and 1019 +/- 38 respectively (p less than 0.001). A risk index without inhibition index, had the corresponding values 366 +/- 14 and 527 +/- 17 (p less than 0.001).

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7105424     DOI: 10.1016/0009-8981(82)90145-0

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  26 in total

1.  Can a relationship reflect the risk of calcium oxalate urolithiasis?

Authors:  P Roca; A Conte; T Riera; F Grases
Journal:  Int Urol Nephrol       Date:  1990       Impact factor: 2.370

2.  Prophylactic and therapeutic properties of a sodium citrate preparation in the management of calcium oxalate urolithiasis: randomized, placebo-controlled trial.

Authors:  Shameez Allie-Hamdulay; Allen L Rodgers
Journal:  Urol Res       Date:  2005-05-04

3.  Calcium oxalate saturation in dialysis patients with and without primary hyperoxaluria.

Authors:  Yoshihide Ogawa; Noriko Machida; Tomohide Ogawa; Masami Oda; Sanehiro Hokama; Yoshiaki Chinen; Atsushi Uchida; Makoto Morozumi; Kimio Sugaya; Yaeko Motoyoshi; Motofumi Hattori
Journal:  Urol Res       Date:  2006-01-24

Review 4.  Risk formulas in calcium oxalate urolithiasis.

Authors:  H G Tiselius
Journal:  World J Urol       Date:  1997       Impact factor: 4.226

5.  Intestinal permeability in subjects from two different race groups with diverse stone-risk profiles.

Authors:  Takalani Theka; Allen Rodgers; Neil Ravenscroft; Sonja Lewandowski
Journal:  Urolithiasis       Date:  2013-01-22       Impact factor: 3.436

6.  A proposed method for approximate estimates of the ion-activity products of calcium oxalate and calcium phosphate in spot-urine samples or in urine samples collected during less well defined periods of time.

Authors:  Hans-Göran Tiselius
Journal:  Urolithiasis       Date:  2013-02-06       Impact factor: 3.436

7.  Effects of different doses of alkaline citrate on urine composition and crystallization of calcium oxalate.

Authors:  C Berg; L Larsson; H G Tiselius
Journal:  Urol Res       Date:  1990

8.  Persistence of 1,25D-induced hypercalciuria in alendronate-treated genetic hypercalciuric stone-forming rats fed a low-calcium diet.

Authors:  Kevin K Frick; John R Asplin; Christopher D Culbertson; Ignacio Granja; Nancy S Krieger; David A Bushinsky
Journal:  Am J Physiol Renal Physiol       Date:  2014-02-26

9.  Studies on crystalluria in calcium oxalate stone formers.

Authors:  C Ahlstrand; H G Tiselius; L Larsson
Journal:  Urol Res       Date:  1984

10.  Crystal growth of calcium oxalate in urine of stone-formers and normal controls.

Authors:  W Achilles; D Dekanić; M Burk; C Schalk; A Tucak; I Karner
Journal:  Urol Res       Date:  1991
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.